Search Results

Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their key pipeline product UTD2 (utidelone capsule) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of gastric cancer.

Biostar Pharma, Inc. announced today that their core pipeline product utidelone injectable (UTD1) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of breast cancer brain metastasis (BCBM).

SomaLogic, Inc., a leader in proteomics technology, announced that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.

In a remarkable stride towards advancing medical technology, we are thrilled to announce the launch of our groundbreaking BioStar® Transbronchial Aspiration Needle (TBNA) designed to transform the landscape of minimally invasive diagnostics.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Biostar Pharma, Inc. is pleased to announce that the first patient has been enrolled today for a Phase 1 clinical study (BG02-2201; NCT05681000) of its proprietary oral formulation product of utidelone, UTD2 (utidelone capsule) in advanced solid tumor patients in the US.